Novo Nordisk Crashes 15% as Next-Gen Obesity Drug Loses
The weight-loss drug wars reached a decisive inflection point on Monday as Novo Nordisk's shares plummeted nearly 16% — wiping roughly $27 billion off its market capitalization in a single session — after its much-anticipated next-generation obesity treatment CagriSema failed to prove it was at least as effective as Eli Lilly's tirzepatide in a pivotal 84-week clinical trial. The Danish drugmaker's stock fell to $40.07 per share, hitting its lowest level since June 2021 and marking a staggering decline of more than 57% from its 52-week high of $93.80. The REDEFINE 4 Phase III trial, which was designed to demonstrate non-inferiority to Lilly's blockbuster ingredient — the active compound behind both Mounjaro and Zepbound — instead showed CagriSema delivering 23% weight loss at 84 weeks compared to 25.5% for tirzepatide. For a company that once dominated the GLP-1 obesity market with Ozempic and Wegovy, the result represents a potentially existential competitive setback that reshapes the landscape of a market projected to exceed $100 billion by the end of the decade. Meanwhile, Eli Lilly surged 4.5% to $1,055.25, approaching its $995.5 billion market capitalization as it simultaneously launched a new multi-dose KwikPen form of Zepbound offering a full month of treatment in a single device at $299 per month — a calculated one-two punch of clinical superiority and patient convenience that further cements its dominant position.